The PD-1/PD-L1-related effects affect the hematopoietic pathways of MDS, and blocking PD-1 or PD-L1 helps reverse the ineffective hematopoietic environment triggered by MDSCs. The gene discussed is CD274; the disease is myelodysplastic syndrome.